Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics

Samira Dahesh; Mary E. Hensler; Nina M. Van Sorge; Robert E. Gertz; Stephanie Schrag; Victor Nizet; Bernard W. Beall

doi:10.1128/AAC.00461-08

Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics

Samira Dahesh, Mary E. Hensler, Nina M. Van Sorge, Robert E. Gertz, Stephanie Schrag, Victor Nizet, Bernard W. Beall^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Beta-lactam antibiotics (BLAB) are the first-line agents used against group B streptococci (GBS) infection. A clonal set of four independent, invasive GBS isolates with elevated MICs to BLAs were identified that shared a pbp2x mutation (Q557E) corresponding to a resistance-conferring pneumococcal mutation. BLA sensitivity was restored through allelic replacement or complementation with the wild-type pbp2x.

Original language	English
Pages (from-to)	2915-2918
Number of pages	4
Journal	Antimicrobial Agents and Chemotherapy
Volume	52
Issue number	8
DOIs	https://doi.org/10.1128/AAC.00461-08
Publication status	Published - Aug 2008

Keywords

PENICILLIN-BINDING PROTEINS
PNEUMONIAE
1A
2X

Access to Document

10.1128/AAC.00461-08

Cite this

@article{69cedef58b724610b95da08291dddebd,

title = "Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics",

abstract = "Beta-lactam antibiotics (BLAB) are the first-line agents used against group B streptococci (GBS) infection. A clonal set of four independent, invasive GBS isolates with elevated MICs to BLAs were identified that shared a pbp2x mutation (Q557E) corresponding to a resistance-conferring pneumococcal mutation. BLA sensitivity was restored through allelic replacement or complementation with the wild-type pbp2x.",

keywords = "PENICILLIN-BINDING PROTEINS, PNEUMONIAE, 1A, 2X",

author = "Samira Dahesh and Hensler, {Mary E.} and {Van Sorge}, {Nina M.} and Gertz, {Robert E.} and Stephanie Schrag and Victor Nizet and Beall, {Bernard W.}",

year = "2008",

month = aug,

doi = "10.1128/AAC.00461-08",

language = "English",

volume = "52",

pages = "2915--2918",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "8",

}

TY - JOUR

T1 - Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics

AU - Dahesh, Samira

AU - Hensler, Mary E.

AU - Van Sorge, Nina M.

AU - Gertz, Robert E.

AU - Schrag, Stephanie

AU - Nizet, Victor

AU - Beall, Bernard W.

PY - 2008/8

Y1 - 2008/8

N2 - Beta-lactam antibiotics (BLAB) are the first-line agents used against group B streptococci (GBS) infection. A clonal set of four independent, invasive GBS isolates with elevated MICs to BLAs were identified that shared a pbp2x mutation (Q557E) corresponding to a resistance-conferring pneumococcal mutation. BLA sensitivity was restored through allelic replacement or complementation with the wild-type pbp2x.

AB - Beta-lactam antibiotics (BLAB) are the first-line agents used against group B streptococci (GBS) infection. A clonal set of four independent, invasive GBS isolates with elevated MICs to BLAs were identified that shared a pbp2x mutation (Q557E) corresponding to a resistance-conferring pneumococcal mutation. BLA sensitivity was restored through allelic replacement or complementation with the wild-type pbp2x.

KW - PENICILLIN-BINDING PROTEINS

KW - PNEUMONIAE

KW - 1A

KW - 2X

U2 - 10.1128/AAC.00461-08

DO - 10.1128/AAC.00461-08

M3 - Article

SN - 0066-4804

VL - 52

SP - 2915

EP - 2918

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 8

ER -

Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics

Abstract

Keywords

Access to Document

Fingerprint

Cite this